Novartis eyes chief executive shake-up in 2018

September 4, 2017

Swiss pharmaceutical giant Novartis said Monday its chief executive for the past seven years, Joseph Jimenez, will step down in 2018, allowing chief medical officer Vasant Narasimhan to take the reins.

Jimenez, who joined Novartis in 2007 and took over as CEO in 2010, had informed the board of directors of his wish to relinquish his leadership position early next year, Novartis said in a statement.

He will step down on January 31, but has agreed to remain available to provide advice and support until he retires from Novartis on August 31, it added.

"Both from a professional and a personal perspective, this is the right moment to hand the leadership reins of the company to Vas," Jimenez said in the statement, pointing to the company's "strong pipeline" and insisting Novartis was "on a strong path for the future."

"On the personal side, after 10 wonderful years in Switzerland, my family is ready to return to Silicon Valley and the US," he said, adding: "I'm confident that Vas will be an excellent successor."

Narasimhan, who will take over as on February 1, joined Novartis in 2005.

The US citizen, who is 41, holds a medical degree and a public policy degree from Harvard, and previously worked for McKinsey & Company.

The married father of two is currently serving as the global head of drug development and chief medical officer at Novartis.

"We anticipate a smooth transition," Joerg Reinhardt, chairman of the Novartis board said in the statement.

Explore further: Novartis to buy back $5 bn in shares

Related Stories

Novartis to buy back $5 bn in shares

January 25, 2017
Swiss pharmaceutical giant Novartis announced Wednesday a $5.0 billion share buyback even though competition from generics ate away at sales and earnings last year.

Novartis Korea executives charged for bribing doctors

August 13, 2016
Prosecutors have indicted the former chief executive of the South Korean unit of Novartis and five other former and current managers over allegations they illegally paid doctors 2.6 billion won ($2.3 million) in return for ...

Roche 'extremely open' to talks with Novartis: report

October 1, 2013
The head of Swiss pharmaceutical giant Roche is open to renewed cooperation with competitor Novartis, he told the Financial Times in an interview published Tuesday.

Novartis chief sees sales dip until mid-2013

October 7, 2012
Swiss pharmaceutical giant Novartis said Sunday the expiry of a US patent for its leading hypertension drug Diovan caused a drop in turnover that could last into the first half of 2013.

Novartis Q4 net profit rebounds to $2.1 billion

January 23, 2013
(AP)—Swiss drug maker Novartis AG reported a jump in fourth-quarter net profit to $2.08 billion on Wednesday, citing the lack of a $900-million one-time charge it took in the same period the previous year.

Novartis to use Google technology for eye care

July 15, 2014
Swiss drug developer Novartis will team with technology giant Google to develop a "smart" contact lens that could improve some eye conditions or help diabetics manage their disease.

Recommended for you

Study: What patients really think about opioid vs non-opioid medications for chronic pain

August 14, 2018
Prescriptions of opioids for chronic pain has increased dramatically since the 1990s in spite of their known harms. Despite a shortage of scientific studies on the long-term effectiveness of opioids such as morphine, oxycodone ...

Doctors nudged by overdose letter prescribe fewer opioids

August 9, 2018
In a novel experiment, doctors got a letter from the medical examiner's office telling them of their patient's fatal overdose. The response: They started prescribing fewer opioids.

Benzodiazepine and related drug prescriptions have increased among young people in Sweden

August 7, 2018
The prevalence rate of prescriptions for benzodiazepines and benzodiazepine-related drugs (BZD)—medications used to treat anxiety, insomnia, epilepsy and other neuropsychiatric conditions—increased by 22% between 2006 ...

Unwise opioids for wisdom teeth: Study shows link to long-term use in teens and young adults

August 7, 2018
Getting wisdom teeth removed may be a rite of passage for many teens and young adults, but the opioid painkiller prescriptions that many of them receive could set them on a path to long-term opioid use, a new study finds.

Behavioral nudges lead to striking drop in prescriptions of potent antipsychotic

August 1, 2018
A study led by Columbia University's Mailman School of Public Health has found that letters targeting high prescribers of Seroquel (quetiapine), an antipsychotic with potentially harmful side effects in the elderly, significantly ...

US opioid use not declined, despite focus on abuse and awareness of risk

August 1, 2018
Use of prescription opioids in the United States has not substantially declined over the last decade, despite increased attention to opioid abuse and awareness of their risks, finds a study published by The BMJ today.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.